Medy-Tox Inc
086900
Company Profile
Business description
Medy-Tox Inc. is a Korea-based company engaged in the development, manufacture, and marketing of biopharmaceuticals. The company's main product is type-A botulium toxin biopharmaceuticals which are used as remedies for blepharospasms, hemifacial spasms, eye wrinkles, hyperhidrosis diseases and infantile cerebral palsy. The group provides its products under the brand names of Neuronox, Siax and others. It distributes its products within Korean and to overseas markets, such as Japan, China, Russia and Europe, among others.
Contact
641-4, Gak-Ri
Ochang-Eup
Cheongwon363885
KORT: +82 432171555
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
761
Stocks News & Analysis
stocks
We remove our Moat Rating from ASX listed share
Despite a surging share price a weakening competitive position causes a reassessment of our view.
stocks
Best sustainable companies to own in 2026
We believe these companies’ strong ESG management practices give them a long-term advantage.
stocks
New data centre deal for ASX listed REIT
New parternship adds to a growing data centre pipeline in fiscal 2026.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,034.70 | 2.20 | -0.02% |
| CAC 40 | 8,200.11 | 4.90 | 0.06% |
| DAX 40 | 24,787.59 | 248.25 | 1.01% |
| Dow JONES (US) | 48,905.95 | 523.56 | 1.08% |
| FTSE 100 | 9,984.42 | 33.28 | 0.33% |
| HKSE | 26,347.24 | 8.77 | 0.03% |
| NASDAQ | 23,408.61 | 172.98 | 0.74% |
| Nikkei 225 | 51,832.80 | 1,493.32 | 2.97% |
| NZX 50 Index | 13,587.23 | 38.81 | 0.29% |
| S&P 500 | 6,904.70 | 46.23 | 0.67% |
| S&P/ASX 200 | 8,728.60 | 2.60 | 0.03% |
| SSE Composite Index | 4,023.42 | 54.58 | 1.38% |